Imaeda, Miho
Tanaka, Satoshi
Oya-Ito, Tomoko
Uematsu, Mariko
Fujigaki, Hidetsugu
Saito, Kuniaki
Ando, Masahiko
Ozaki, Norio
Funding for this research was provided by:
JSPS KAKENHI (19K17087, 20K07942, 17K00851)
AMED (JP21dk0307103)
Article History
Received: 29 January 2024
Accepted: 22 June 2024
First Online: 9 July 2024
Declarations
:
: This study was approved by the Ethics Review Committee of the Nagoya University Graduate School of Medicine (2009 − 0853). Written informed consent was obtained from all participants.
: Not applicable.
: N. Ozaki has received research support or speakers’ honoraria from, or has served as a joint researcher with, or a consultant to, Sumitomo Pharma, Eisai, Otsuka, KAITEKI, Mitsubishi Tanabe, Eli Lilly, Mochida, Daiichi-Sankyo, TSUMURA, Takeda, Meiji Seika Pharma, EA Pharma, Viatris, Ricoh, Nippon Boehringer Ingelheim, Lundbeck Japan, Nihon Medi-Physics, and Nippon Chemiphar, outside the submitted work.